Alzamend Historical Balance Sheet

ALZN Stock

USD 1.26 0.03 2.33%

Trend analysis of Alzamend Neuro balance sheet accounts such as Net Tangible Assets of 3.3 M, Accounts Payable of 3.1 M or Other Assets of 0.0 provides information on Alzamend Neuro's total assets, liabilities, and equity, which is the actual value of Alzamend Neuro to its prevalent stockholders. By breaking down trends over time using Alzamend Neuro balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Alzamend Neuro latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Alzamend Neuro is a good buy for the upcoming year.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alzamend Neuro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.

About Alzamend Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Alzamend Neuro at a specified time, usually calculated after every quarter, six months, or one year. Alzamend Neuro Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Alzamend Neuro and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Alzamend currently owns. An asset can also be divided into two categories, current and non-current.

Alzamend Neuro Balance Sheet Chart

At this time, Alzamend Neuro's Total Current Liabilities is very stable compared to the past year. As of the 27th of November 2024, Accounts Payable is likely to grow to about 3.1 M, while Net Tangible Assets are likely to drop about 3.3 M.

Total Current Liabilities Accounts Payable Net Receivables Total Assets

Total Current Liabilities

Total Current Liabilities is an item on Alzamend Neuro balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Alzamend Neuro are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Alzamend Neuro obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Alzamend Neuro are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Total Assets

Total assets refers to the total amount of Alzamend Neuro assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Alzamend Neuro books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Most accounts from Alzamend Neuro's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Alzamend Neuro current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alzamend Neuro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.At this time, Alzamend Neuro's Total Current Liabilities is very stable compared to the past year. As of the 27th of November 2024, Accounts Payable is likely to grow to about 3.1 M, while Net Tangible Assets are likely to drop about 3.3 M.

	2023	2024 (projected)
Deferred Long Term Liabilities	67.5K	60K
Net Receivables	14.6K	13.9K

Deferred Long Term Liab Net Receivables

Alzamend Neuro balance sheet Correlations

	Total Current Liabilities	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Net Receivables	Deferred Long Term Liab	Total Current Assets	Common Stock	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Capital Stock	Net Working Capital
Total Current Liabilities		0.31	-0.95	0.98	0.14	-0.27	-0.78	0.1	-0.19	0.03	0.66	0.97	-0.18	-0.72	-0.12	0.14	0.14	0.83	-0.75	-0.96	-0.79	0.79	0.86	-0.16	-0.54	-0.19
Net Tangible Assets	0.31		-0.56	0.43	-0.08	0.0	-0.19	0.92	0.46	0.88	0.67	0.22	0.79	-0.7	-0.91	0.92	0.92	0.68	-0.69	-0.21	-0.65	0.76	0.21	0.81	0.16	0.78
Retained Earnings	-0.95	-0.56		-0.97	-0.01	0.19	0.72	-0.34	0.02	-0.25	-0.82	-0.91	-0.05	0.86	0.34	-0.36	-0.36	-0.93	0.88	0.92	0.89	-0.91	-0.82	-0.07	0.44	-0.03
Accounts Payable	0.98	0.43	-0.97		-0.02	-0.1	-0.72	0.23	-0.03	0.14	0.7	0.94	-0.07	-0.75	-0.22	0.24	0.24	0.86	-0.77	-0.94	-0.78	0.84	0.84	-0.05	-0.44	-0.08
Other Assets	0.14	-0.08	-0.01	-0.02		-0.79	-0.12	-0.13	-0.39	0.05	-0.08	0.16	-0.01	0.06	-0.07	0.06	0.06	0.14	0.05	-0.05	-0.13	0.07	0.22	-0.01	-0.08	-0.01
Net Receivables	-0.27	0.0	0.19	-0.1	-0.79		0.15	0.03	0.23	-0.13	-0.28	-0.2	-0.08	0.29	0.15	-0.16	-0.16	-0.24	0.29	0.19	0.31	-0.24	-0.19	-0.09	0.07	-0.07
Deferred Long Term Liab	-0.78	-0.19	0.72	-0.72	-0.12	0.15		0.16	0.59	0.22	-0.35	-0.79	0.38	0.45	-0.14	0.12	0.12	-0.5	0.52	0.73	0.72	-0.42	-0.5	0.36	0.85	0.4
Total Current Assets	0.1	0.92	-0.34	0.23	-0.13	0.03	0.16		0.75	0.98	0.56	-0.01	0.94	-0.58	-0.98	0.98	0.98	0.5	-0.54	-0.01	-0.38	0.66	0.05	0.95	0.52	0.94
Common Stock	-0.19	0.46	0.02	-0.03	-0.39	0.23	0.59	0.75		0.72	0.27	-0.28	0.76	-0.27	-0.68	0.67	0.67	0.08	-0.2	0.18	0.13	0.32	-0.16	0.75	0.86	0.76
Total Assets	0.03	0.88	-0.25	0.14	0.05	-0.13	0.22	0.98	0.72		0.49	-0.08	0.98	-0.52	-1.0	0.99	0.99	0.44	-0.47	0.08	-0.33	0.6	-0.01	0.98	0.58	0.97
Short Long Term Debt Total	0.66	0.67	-0.82	0.7	-0.08	-0.28	-0.35	0.56	0.27	0.49		0.6	0.35	-0.98	-0.55	0.58	0.58	0.85	-0.97	-0.67	-0.85	0.88	0.6	0.38	-0.1	0.34
Other Current Liab	0.97	0.22	-0.91	0.94	0.16	-0.2	-0.79	-0.01	-0.28	-0.08	0.6		-0.29	-0.65	-0.01	0.03	0.03	0.79	-0.69	-0.98	-0.75	0.73	0.9	-0.28	-0.58	-0.31
Total Stockholder Equity	-0.18	0.79	-0.05	-0.07	-0.01	-0.08	0.38	0.94	0.76	0.98	0.35	-0.29		-0.36	-0.95	0.95	0.95	0.25	-0.31	0.28	-0.15	0.42	-0.21	1.0	0.68	1.0
Current Deferred Revenue	-0.72	-0.7	0.86	-0.75	0.06	0.29	0.45	-0.58	-0.27	-0.52	-0.98	-0.65	-0.36		0.58	-0.6	-0.6	-0.84	1.0	0.71	0.89	-0.91	-0.58	-0.39	0.12	-0.35
Net Debt	-0.12	-0.91	0.34	-0.22	-0.07	0.15	-0.14	-0.98	-0.68	-1.0	-0.55	-0.01	-0.95	0.58		-1.0	-1.0	-0.52	0.54	0.01	0.41	-0.67	-0.07	-0.96	-0.51	-0.95
Cash	0.14	0.92	-0.36	0.24	0.06	-0.16	0.12	0.98	0.67	0.99	0.58	0.03	0.95	-0.6	-1.0		1.0	0.54	-0.57	-0.03	-0.44	0.69	0.08	0.95	0.49	0.94
Cash And Short Term Investments	0.14	0.92	-0.36	0.24	0.06	-0.16	0.12	0.98	0.67	0.99	0.58	0.03	0.95	-0.6	-1.0	1.0		0.54	-0.57	-0.03	-0.44	0.69	0.08	0.95	0.49	0.94
Common Stock Total Equity	0.83	0.68	-0.93	0.86	0.14	-0.24	-0.5	0.5	0.08	0.44	0.85	0.79	0.25	-0.84	-0.52	0.54	0.54		-0.84	-0.78	-0.85	0.94	0.84	0.27	-0.27	0.23
Common Stock Shares Outstanding	-0.75	-0.69	0.88	-0.77	0.05	0.29	0.52	-0.54	-0.2	-0.47	-0.97	-0.69	-0.31	1.0	0.54	-0.57	-0.57	-0.84		0.73	0.91	-0.91	-0.59	-0.34	0.19	-0.3
Non Current Liabilities Total	-0.96	-0.21	0.92	-0.94	-0.05	0.19	0.73	-0.01	0.18	0.08	-0.67	-0.98	0.28	0.71	0.01	-0.03	-0.03	-0.78	0.73		0.73	-0.75	-0.88	0.26	0.52	0.3
Other Current Assets	-0.79	-0.65	0.89	-0.78	-0.13	0.31	0.72	-0.38	0.13	-0.33	-0.85	-0.75	-0.15	0.89	0.41	-0.44	-0.44	-0.85	0.91	0.73		-0.81	-0.63	-0.18	0.47	-0.14
Other Stockholder Equity	0.79	0.76	-0.91	0.84	0.07	-0.24	-0.42	0.66	0.32	0.6	0.88	0.73	0.42	-0.91	-0.67	0.69	0.69	0.94	-0.91	-0.75	-0.81		0.72	0.44	-0.05	0.41
Total Liab	0.86	0.21	-0.82	0.84	0.22	-0.19	-0.5	0.05	-0.16	-0.01	0.6	0.9	-0.21	-0.58	-0.07	0.08	0.08	0.84	-0.59	-0.88	-0.63	0.72		-0.2	-0.4	-0.22
Net Invested Capital	-0.16	0.81	-0.07	-0.05	-0.01	-0.09	0.36	0.95	0.75	0.98	0.38	-0.28	1.0	-0.39	-0.96	0.95	0.95	0.27	-0.34	0.26	-0.18	0.44	-0.2		0.67	1.0
Capital Stock	-0.54	0.16	0.44	-0.44	-0.08	0.07	0.85	0.52	0.86	0.58	-0.1	-0.58	0.68	0.12	-0.51	0.49	0.49	-0.27	0.19	0.52	0.47	-0.05	-0.4	0.67		0.69
Net Working Capital	-0.19	0.78	-0.03	-0.08	-0.01	-0.07	0.4	0.94	0.76	0.97	0.34	-0.31	1.0	-0.35	-0.95	0.94	0.94	0.23	-0.3	0.3	-0.14	0.41	-0.22	1.0	0.69

Click cells to compare fundamentals

Alzamend Neuro Account Relationship Matchups

Alzamend Neuro balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Current Liabilities	992.3K	899.6K	1.2M	2.9M	3.2M	3.4M
Net Tangible Assets	821.6K	2.0M	13.4M	3.0M	3.5M	3.3M
Retained Earnings	(11.8M)	(16.8M)	(29.2M)	(44.1M)	(54.0M)	(51.3M)
Accounts Payable	929.6K	503.6K	1.2M	2.9M	2.9M	3.1M
Net Receivables	424.4K	285.4K	194.3K	16.2K	14.6K	13.9K
Total Current Assets	1.8M	2.9M	14.4M	5.8M	455.2K	432.5K
Common Stock	6.5K	6.7K	9.5K	9.7K	69.0	65.55
Total Assets	1.8M	2.9M	14.5M	5.9M	631.6K	600.0K
Other Current Liab	62.7K	60.7K	2.1K	2.9M	3.2M	3.4M
Total Stockholder Equity	821.7K	2.0M	13.4M	3.0M	(2.6M)	(2.5M)
Net Debt	(90.2K)	(1.6M)	(14.1M)	(5.1M)	(75.3K)	(79.1K)
Cash	90.3K	1.9M	14.1M	5.1M	376.0K	357.2K
Cash And Short Term Investments	90.3K	1.9M	14.1M	5.1M	376.0K	357.2K
Common Stock Total Equity	6.5K	6.7K	9.5K	9.7K	11.1K	8.5K
Liabilities And Stockholders Equity	1.8M	2.9M	14.5M	5.9M	631.6K	600.0K
Other Current Assets	1.5M	614.6K	349.7K	694.9K	79.2K	75.2K
Other Stockholder Equity	27.6M	33.7M	57.4M	62.0M	51.4M	46.7M
Total Liab	992.3K	899.6K	1.2M	2.9M	3.2M	1.9M
Net Invested Capital	821.6K	2.3M	13.4M	3.0M	(2.3M)	(2.2M)
Capital Stock	6.6K	6.8K	9.5K	9.7K	69.0	65.55
Net Working Capital	821.7K	2.0M	13.2M	3.0M	(2.8M)	(2.6M)

Pair Trading with Alzamend Neuro

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alzamend Neuro position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alzamend Neuro will appreciate offsetting losses from the drop in the long position's value.

Moving together with Alzamend Stock

0.8	FDMT	4D Molecular Therapeutics	Pair Corr
0.67	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.7	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr

Moving against Alzamend Stock

0.75	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.57	NAMS	NewAmsterdam Pharma	Pair Corr
0.46	MNOV	MediciNova	Pair Corr
0.45	PHVS	Pharvaris BV	Pair Corr
0.43	OPT	Opthea	Pair Corr

The ability to find closely correlated positions to Alzamend Neuro could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alzamend Neuro when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alzamend Neuro - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alzamend Neuro to buy it.

The correlation of Alzamend Neuro is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alzamend Neuro moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alzamend Neuro moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Alzamend Neuro can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Alzamend Neuro offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alzamend Neuro's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alzamend Neuro Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alzamend Neuro Stock:

How To Invest In Alzamend

Details

Is Alzamend Stock a good investment?

Details

What is Alzamend Neuro's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.

You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(142.87)

Return On Assets

(2.14)

Return On Equity

(44.08)

The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Alzamend Historical Balance Sheet

About Alzamend Balance Sheet Analysis

Alzamend Neuro Balance Sheet Chart

Total Current Liabilities

Accounts Payable

Total Assets

Alzamend Neuro balance sheet Correlations

Alzamend Neuro Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Alzamend Neuro balance sheet Accounts

Pair Trading with Alzamend Neuro

Moving together with Alzamend Stock

Moving against Alzamend Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Invested Capital	+ 1.0	Total Stockholder Equity
Net Working Capital	+ 1.0	Total Stockholder Equity
Common Stock Shares Outstanding	+ 1.0	Current Deferred Revenue
Cash And Short Term Investments	+ 1.0	Cash
Net Working Capital	+ 1.0	Net Invested Capital
Cash	+ 0.99	Total Assets

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Assets
Non Current Liabilities Total	- 0.98	Other Current Liab
Current Deferred Revenue	- 0.98	Short Long Term Debt Total
Net Debt	- 0.98	Total Current Assets